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Abstract
The objective of this retrospective cohort study was to determine the effect of tumor necro-
sis factor inhibitor (TNFi) therapy on the risk of head and neck cancer (HNC) recurrence or
HNC-attributable death in patients with rheumatoid arthritis (RA). RA patients with HNC
were assembled from the US national Veterans’ Affairs (VA) administrative databases, and
diagnoses confirmed and data collected by electronic medical record review. The cohort
was divided into those treated with non-biologic disease-modifying anti-rheumatic drugs
(nbDMARDs) versus TNF inhibitors (TNFi) after a diagnosis of HNC. Likelihood of a com-
posite endpoint of recurrence or HNC-attributable death was determined by Cox propor-
tional hazards regression. Of 180 patients with RA and HNC, 31 were treated with TNFi and
149 with nbDMARDs after the diagnosis of HNC. Recurrence or HNC-attributable death
occurred in 5/31 (16.1%) patients in the TNFi group and 44/149 (29.5%) patients in the
nbDMARD group (p = 0.17); it occurred in 2/16 (13%) patients who received TNFi in the
year prior to HNC diagnosis but not after. Overall stage at diagnosis (p = 0.03) and stage 4
HNC (HR 2.49 [CI 1.06–5.89]; p = 0.04) were risk factors for recurrence or HNC-attributable
death; treatment with radiation or surgery was associated with a lower risk (HR 0.35 [CI
0.17–0.74]; p = 0.01 and HR 0.39 [CI 0.20–0.76]; p = 0.01 respectively). Treatment with
TNFi was not a risk factor for recurrence or HNC-attributable death (HR 0.75; CI 0.31–1.85;
p = 0.54). We conclude that treatment with TNFi may be safe in patients with RA and HNC,
especially as the time interval between HNC treatment and non-recurrence increases. In
this study, TNF inhibition was not associated with an increase in recurrence or HNC-attribut-
able death.
Introduction
Head and neck cancer (HNC) is a relatively common entity in the veteran population. Its fre-
quency likely reflects the high prevalence of tobacco and alcohol use in this group, two well-
known risk factors for this type of malignancy [1]. Treatment with tumor necrosis factor inhib-
itors (TNFi) in patients with rheumatoid arthritis (RA) increases the risk of certain cancers.
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We and others have reported on the increased risk of non-melanoma skin cancer in patients
with RA treated with TNFi compared to those treated with non-biologic disease-modifying
anti-rheumatic drugs (nbDMARDs) [2–5]. However, the effect of TNFi on the natural history
of individual solid tumors such as HNC has not been adequately examined.
Rheumatologists are often faced with difficult clinical situations regarding the potential
risks and effects of immunosuppression on an individual patient’s comorbidities including a
history of malignancy. In the case of HNC, which is strongly associated with human papilloma
virus infection, there is reason for additional concern as immunosuppression may potentially
play a role in accelerating the natural history of the cancer. Hence a systematic analysis of the
impact of TNF antagonism on the natural history of HNC will help guide rheumatologists in
the management of patients with RA and a history of HNC.
The United States (US) national Veterans’ Affairs (VA) administrative databases offered the
opportunity to assemble a large cohort of patients with both RA and HNC, to examine this
issue. We hypothesized that TNFi used in patients with a known diagnosis of HNC may
increase the risk of recurrence or HNC-attributable death. Among patients with RA who had
been diagnosed with HNC, we examined the risk factors for a composite endpoint of recur-
rence or HNC-attributable death, with a particular interest in the effect of TNFi therapy on this
outcome. The goal of our study was to determine the impact of TNF antagonism on HNC
recurrence or HNC-attributable death in patients with RA.
Methods
Data Sources
This study was approved by the institutional review board of the St. Louis VA medical center.
We acquired data from the VA’s Austin Information Technology Center (AITC) and the Phar-
macy Benefits Management (PBM) databases, which contain the VA’s centralized national
administrative data. AITC data included all inpatient and outpatient International Classifica-
tion of Diseases, Version 9, Clinical Modification (ICD-9-CM) diagnosis codes, encounter
data, and demographic data. PBM data included all inpatient and outpatient pharmacy data.
Data from both the AITC and PBM were merged into a single database. Patients identified
with possible RA and HNC from this database subsequently underwent review of electronic
medical records using the Compensation and Pension Records Interchange (CAPRI), an elec-
tronic system that can be used to access individual patient electronic medical records at a
national level in the VA healthcare system. CAPRI review was performed to confirm the diag-
noses of RA and HNC, and to collect additional variables not available from the national VA
administrative databases. All patient information was anonymized and de-identified prior to
analysis.
Study Cohort
We constructed our cohort of veterans with RA and HNC in two steps. In the first step, we
screened VA national administrative databases for veterans who met the following criteria
between October 1, 1998 and September 30, 2008: 1) received an ICD-9-CM diagnosis code of
RA, 2) received at least one prescription for a DMARD from the VA, 3) had at least a 4-month
history of receiving medication from the VA prior to first DMARD prescription (in order to
identify the date of first RA treatment) 4) had at least two separate clinic visits during the study
period (to allow for follow-up), and 5) had an ICD-9-CM code for HNC. In the second step,
the electronic medical records of all veterans meeting these criteria were reviewed by the first
author (CP), a board-certified internist and rheumatology fellow, to verify the presence of both
RA and HNC. Subjects who were not confirmed by electronic medical record review to have
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both RA and HNC during the study period were excluded. The final cohort consisted of all
patients with a confirmed diagnosis of both RA and HNC during the study period, who
received a DMARD after diagnosis of HNC.
Definitions
Rheumatoid Arthritis (RA). We screened for RA using an algorithm validated by Singh
et al [6], requiring both of the following from administrative data: 1) the occurrence of an ICD-
9-CM code for RA (714.0, 714.1, 714.2, or 714.81) on at least one occasion in either the inpa-
tient or outpatient record, and 2) the receipt of a prescription for a DMARD on at least one
occasion. Electronic medical records of patients identified using this algorithm were reviewed,
and RA diagnosis was confirmed if a physician noted that a patient had RA in the narrative
text or in a written problem list. RA was considered present if the patient was noted to have
“likely” or “probable” RA, but not if the qualifier was “possible,” “suggestive of” or if the diag-
nosis was presented in a differential diagnosis format (i.e., RA vs. osteoarthritis), or if the diag-
nosis of RA was later found to be erroneous.
Disease Modifying Anti-Rheumatic Drugs (DMARDs). DMARDs were characterized as
nbDMARDs and TNFi. The following drugs were defined as nbDMARDs: hydroxychloro-
quine, methotrexate, sulfasalazine, leflunomide, azathioprine, cyclophosphamide, cyclosporine,
oral and injectable gold, and penicillamine. TNFi included etanercept, infliximab, and adalimu-
mab. A patient ever treated with a TNFi after HNC diagnosis was considered TNFi-exposed.
Head and Neck Cancer (HNC). We screened for HNC by looking for a single occurrence
of the following ICD-9-CM diagnosis codes in VA administrative data: ICD-9-CM codes for
cancer of lip, tongue, major/minor salivary glands, gum, mouth, oropharynx, nasopharynx,
hypopharynx (140.0–149.9, 195.0, 196.0), carcinoma in situ (230.0, 231.0), cancer of the nasal
cavity, middle ear, sinuses, larynx (160.0–161.9). Electronic medical records of patients identi-
fied using this algorithm were subsequently reviewed, and HNC was considered present if a cli-
nician stated in a narrative note that the patient had ever had HNC, or if a biopsy showed
HNC (including carcinoma of the lip, tongue, major/minor salivary glands, gum, mouth, oro-
pharynx, nasopharynx, hypopharynx, nasal cavity, middle ear, sinuses, or larynx). HNC histol-
ogy was determined based on pathology or the narrative text of clinician notes. Narrative text
of clinician notes describing HNC as the “probable” or “likely” diagnosis were accepted as a
diagnosis of HNC; narrative text of clinician notes describing HNC as “possible” was not
accepted as a diagnosis of HNC.
Covariates. Covariates obtained through complete review of VA electronic medical rec-
ords included age, race, gender, smoking (ever/never at the time of HNC diagnosis) and alco-
hol use (current/not current at the time of diagnosis), indicators of RA severity (extra-articular
disease, history of joint replacement, and rheumatoid factor positivity), and stage and treat-
ment modality of HNC (chemotherapy, radiation, surgery). Covariates obtained through VA
administrative databases included elements of the modified Romano implementation of the
Charlson comorbidity index [7], and history of prior malignancy.
Outcomes. Recurrence was defined as progressive HNC after prior treatment. Recurrence
was determined by medical record review. A patient was considered to have recurred if an
oncologist used the term “recurrence” or “progression,” or if subsequent staging showed an
advance in stage. Death was considered to be HNC-attributable if the death would most likely
not have occurred in the absence of HNC. A patient was considered to meet our primary com-
posite outcome of HNC recurrence or HNC-attributable death if the patient had HNC recur-
rence, HNC-attributable death, or both.
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Statistical Analysis
Multiple Cox regression was used to perform time-to-event analyses including a multivariate
model examining risk factors for recurrent HNC or HNC-attributable death using time-vary-
ing covariates. TNFi therapy status was modeled as a time-varying covariate, though only three
subjects switched into the TNFi exposure group post- HNC diagnoses. All other risk factors
including smoking and alcohol use were not modeled as time-varying covariates due to the
sporadic and inconsistent documentation of smoking status and alcohol use in the medical rec-
ords. Multivariate survival regression models using time-varying covariates do not assume pro-
portional hazards, hence this assumption was not tested. Chi-square, t-tests, and Wilcoxon
rank sum tests were used to assess baseline differences between the groups. The three subjects
who switched treatment groups were included in the TNFi group for these comparisons. A
two-sided p-value of<0.05 was considered statistically significant. Outcome risk was described
using hazard ratios (HRs). All analyses were performed using SAS software version 6.12 (SAS
Institute, Cary, NC). Kaplan-Meier time-to-event curves were created using R software version
2.5.1 (R Foundation, Vienna, Austria).
Results
Of the 806 patients identified through the VA administrative databases with ICD-9-CM codes
for RA and HNC, 524 were excluded because the diagnoses of RA and HNC were not con-
firmed by electronic medical record review. Twenty-seven were excluded because they received
no DMARD after HNC diagnosis. None were excluded because age, gender, or race could not
be determined. Two hundred and fifty-five patients had both RA and HNC after validation by
electronic medical record review. Of these, 75 patients had HNC diagnosis prior to the cohort
start date of October 1, 1998 and were excluded. Our final cohort included 180 patients with
both RA and HNC. Of these, 31 patients were treated with TNFi after the diagnosis of HNC,
and 149 were treated only with nbDMARDs after HNC diagnosis (Fig 1). Of the 31 who
received TNFi after HNC diagnosis, 28 had received TNFi before the diagnosis of HNC as well.
Of note, 16 subjects in the nbDMARD group were treated with TNFi within one year prior to
HNC diagnosis and not subsequently treated with these agents, likely reflecting rheumatolo-
gists’ concern that treatment may accelerate the natural history of HNC.
Demographic and clinical characteristics of these patients are presented in Table 1. The
cohort was predominantly male, Caucasian and over 60 years of age with a high prevalence of
smoking and alcohol use. The Romano score for co-morbidities, although slightly higher in the
nbDMARD group (mean 5.4) compared to the TNFi group (mean 3.9), was not significantly
different (p = 0.07) between the groups. Markers of RA disease severity such as the presence of
extra-articular RA (p = 0.69), history of joint replacement (p = 0.75), and rheumatoid factor
positivity (p = 0.52) were similar between the groups. Current alcohol use was the only socio-
demographic variable which was significantly different between the two groups (67.7% TNFi
vs. 43.6% nbDMARD, p = 0.04). Patients were diagnosed with HNC at a mean of 12.6 years
after their diagnosis of RA in the nbDMARD group compared to 12.3 years in the TNFi group;
this difference reached borderline significance (p = 0.05).
There were no differences in HNC stage at the time of first diagnosis between the two
groups (p = 0.64). Stage 1 was the presenting stage for 19.4% of those in the TNFi group and
22.1% of those in the nbDMARD group; percentages were similar for stage 2 (25.8% vs 15.4%),
stage 3 (6.4% vs 12.1%), stage 4 (32.2% vs 34.9%), and unknown (16.1% vs 15.4%). Among the
16 subjects treated with TNFi prior to but not after HNC diagnosis, there were 3 subjects in
stage 1 (19%), 3 in stage 2 (19%), 6 in stage 3 (38%), 3 in stage 4 (19%), and 1 unknown stage
(6%) (percentages rounded). There were no differences between the two groups in the
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Fig 1. Study flow diagram.
doi:10.1371/journal.pone.0143286.g001
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treatment modalities for HNC including chemotherapy (p = 0.73), radiation (p = 0.47), and
surgery (p = 0.99).
HNC recurrence or HNC-attributable death occurred at a mean of 17.0 months after initial
diagnosis of HNC in the TNFi group, and 16.7 months after initial diagnosis in the nbDMARD
group (p = 0.59). HNC recurrence or HNC-attributable death occurred in 5/31 (16.1%) in the
TNFi group and 44/149 (29.5%) in the nbDMARD group (p = 0.17). Among the three subjects
who received TNFi after but not before HNC diagnosis, one subject had recurrence and HNC-
attributable death. Among the 16 subjects who received TNFi before but not after HNC diag-
nosis, there were 2 subjects who had recurrence and HNC-attributable death. Details of the
duration of follow-up of HNC in terms of time to recurrence or death andcensorship in the
two groups are shown in Table 2.
In an adjusted, multivariate model, overall stage at diagnosis (p = 0.03) and stage 4 cancer
were risk factors for recurrence or HNC-attributable death (HR 2.49 [CI 1.06–5.89]; p = 0.04);
treatment with radiation or surgery was associated with a lower risk of recurrence or HNC-
attributable death (HR 0.35 [CI 0.17–0.74]; p = 0.01 and HR 0.39 [CI 0.20–0.76]; p = 0.01
respectively) (Table 3). Exposure to TNFi was not a risk factor for our primary composite out-
come of HNC recurrence or HNC-related death (HR 0.75; CI 0.31–1.85; p = 0.54) (Table 3 and
Fig 2).
Table 1. Demographic and clinical characteristics of RA patients with head and neck cancer.








Mean age in years (SD) 63.9 (7.8) 66.0 (9.1) 0.24
Sex (% male) 31 (100%) 147 (98.7%) 0.52
Race (% Caucasian) 28 (90.3%) 122 (81.9%) 0.38
Current smoking (%) 16 (51.6%) 85 (58.6%) 0.61
Ever smoking (%) 28 (90.3%) 141 (94.6%) 0.50
Current alcohol (%) 21 (67.7%) 65 (43.6%) 0.04
Ever alcohol (%) 27 (87.1%) 111 (74.5%) 0.30
Mean modiﬁed Romano score (SD) 3.9 (4.5) 5.4 (4.1) 0.07
Extra-articular RA (%) 5 (16.1%) 17 (11.4%) 0.69
Joint replacement (%) 5 (16.1%) 18 (12.1%) 0.75
Rheumatoid factor positive (%) 23 (74.2%) 98 (65.8%) 0.52
Mean years from RA diagnosis to head and neck cancer diagnosis (SD) 12.3 (10.8) 12.6 (12.4) 0.05‡
Prior malignancy (%) 14 (45.2%) 88 (59.1%) 0.16
Chemotherapy (%) 10 (32.3%) 53 (35.6%) 0.73
Radiation (%) 25 (80.7%) 111 (74.5%) 0.47
Surgery (%) 16 (51.6%) 77 (51.7%) 0.99
Remission (%) 27 (87.1%) 110 (73.8%) 0.11
Mean months from head and neck cancer diagnosis to recurrence or HNC-attributable
death
17.0 (7.4) 16.7 (13.1) 0.59‡
Head and neck cancer recurrence or HNC-attributable death (%) 5 (16.1%) 44 (29.5%) 0.17
* Exposure to TNFi therapy after head and neck cancer diagnosis assigns subjects to this group irrespective of whether they were exposed to TNFi
therapy prior to the malignancy diagnosis
** Exposed only to non-biologic DMARDs after head and neck cancer diagnosis
‡Wilcoxon Rank-sum Test
doi:10.1371/journal.pone.0143286.t001
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When subjects with evaluable stage were grouped by early (stage 1 and 2) and late (stage 3+)
disease, those who received TNFi at any time (before or after HNC diagnosis) had a similar
unadjusted rate of HNC recurrence or HNC-attributable death to those who only received
nbDMARDs for early stage HNC (3/18, [17%] vs 14/52 [27%], p = 0.38), and significantly
lower rate of unadjusted HNC recurrence or HNC-attributable death among those with late
stage HNC (4/24, [17%] vs 27/60, [45%], p = 0.02). However, exposure to TNFi was not associ-
ated with either risk or protection from HNC recurrence or HNC-attributable death in our
multivariate model as described above.
Table 2. Duration of follow-up of head and neck cancer in the two treatment groups.
Time to recurrence or HNC-attributable death in months Mean (SD) Median Minimum Maximum
TNF inhibitor therapy 13.5 (7.9) 12 2 26
Non-biologic DMARD therapy 11.3 (10.6) 9 0.4 66
Time to censorship in months
TNF inhibitor therapy 40.3 (28.2) 38 1 93
Non-biologic DMARD therapy 42.4 (32.8) 31 1 127
doi:10.1371/journal.pone.0143286.t002





HR (95% CI) p-
value
N 60 120
Mean age in years (SD) 66.7 (9.8) 65.1 (8.5) 1.02 (0.98–
1.06)
0.35
TNF inhibitor therapy after diagnosis (regardless of exposed prior) 8 (13.3%) 23 (19.2%) 0.75 (0.31–
1.85)
0.54
Stage at diagnosis (row %) overall 0.03
stage 1 11 (18.3%) 28 (23.3%) ref
stage 2 5 (8.3%) 26 (21.7%) 0.47(0.16–1.39) 0.17
stage 3 5 (8.3%) 15 (12.5%) 1.33 (0.47–
4.06)
0.62
stage 4 + 30 (50.0%) 32 (26.7%) 2.49 (1.06–
5.89)
0.04
unknown 9 (15.0%) 19 (15.8%) 0.92 (0.36–
2.33)
0.85
Mean years from RA diagnosis to head and neck cancer
diagnosis (SD)
11.4 (13.4) 9.4 (9.8) 1.10(0.99–
1.24)*
0.09
Smoking, ever** 42 (70.0%) 63 (52.5%) 1.80 (0.97–
3.33)
0.06
Alcohol, current** 29 (48.3%) 57 (47.5%) 0.94 (0.55–
1.63)
0.83
Mean modiﬁed Romano score (SD) 5.5 (4.0) 4.9 (4.3) 1.03 (0.96–
1.11)
0.38
Radiation 44 (73.3%) 92 (76.7%) 0.35 (0.17–
0.74)
0.01
Chemotherapy 26 (43.3%) 37 (30.8%) 0.78 (0.37–
1.62)
0.51
Surgery 26 (43.3%) 67 (55.8%) 0.39 (0.20–
0.76)
0.01
* Natural log to correct for non-normality
** Measured at the time of HNC diagnosis
doi:10.1371/journal.pone.0143286.t003
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A sensitivity analysis restricted to biopsy-proven cancers, defined as those with documented
histology (n = 178), showed similar results to our original analysis of 180 patients, with the
same risk factors emerging as significant with similar hazard ratios. The sensitivity analysis
showed that stage 4 cancer was a risk factor for recurrence or HNC-attributable death (HR
2.68 [CI 1.13–6.36]; p = 0.03); treatment with radiation or surgery was associated with a lower
risk of recurrence or HNC-attributable death (HR 0.35 [CI 0.17–0.73]; p = 0.01 and HR 0.40
[CI 0.20–0.79]; p = 0.01 respectively).
Discussion
In an observational cohort of RA patients with HNC derived from the US VA’s national
administrative databases, we found that treatment with TNFi may not be associated with an
increased risk of recurrence or death from head and neck cancer. Our data suggest that it may
be safe to prescribe TNFi to patients with HNC and RA.
A few case reports have described HNC in patients on TNFi therapy. A patient with Crohn’s
disease on infliximab therapy developed squamous cell carcinoma of the base of the tongue,
which after a complete response to treatment with chemotherapy and radiation, recurred after
resumption of infliximab for Crohn’s disease [8]. Another report described an epidermoid car-
cinoma of the buccal mucosa in a patient with RA detected after etanercept was initiated [9].
Another patient with RA on etanercept, previously treated with infliximab and adalumimab,
developed two primary squamous cell carcinomas of the tongue 22 months apart, which
responded to surgery and radiation, with discontinuation of etanercept [10]. We reported on a
Fig 2. Survival curves for a composite outcome of head and neck cancer (HNC) recurrence or HNC-attributable death in RA patients exposed to
TNF inhibitor therapy and non-biologic (nb) DMARDs.
doi:10.1371/journal.pone.0143286.g002
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patient with ankylosing spondylitis who developed an invasive squamous cell carcinoma of the
lower lip after two years of adalimumab therapy [11].
Although these case reports indicate that TNFi may influence the development and recur-
rence of HNC in patients with various inflammatory diseases, the effect of exposure to TNFi
on the risk of recurrence or HNC-attributable death has not been previously examined in a rig-
orous manner. As expected, our study showed that stage at diagnosis and advanced stage dis-
ease adversely affected the risk of our composite outcome, and treatment with radiation and
surgery was protective [12]. Smoking and alcohol use are important risk factors for HNC and
traditionally have accounted for 80–90% of the risk for these cancers [13] Smoking and alcohol
use, both current and past, was high in our cohort, but neither emerged as a risk factor for
HNC recurrence or death. Advanced stage disease, that is, stage 3 and 4 disease, is a prognostic
indicator of poor survival, as shown in a large series of four hundred and fifteen patients with
HNC [14]. Surgery and radiation as treatment modalities may be surrogate markers of earlier,
less advanced disease and were associated with decreased risk for HNC recurrence or death in
our study.
Although the risk for overall malignancy with the use of TNFi in RA has been studied exten-
sively, the risk for site or organ specific malignancies has not been examined as thoroughly,
with the possible exception of skin cancer. As we and other investigators have shown, patients
with RA on TNFi appear to be at an increased risk for non-melanoma skin cancer [2–4]. Such
a risk may not extend to other solid tumors [3–5] including recurrence or HNC-attributable
death, based on the results of this study. Two meta-analyses which examined this issue found
that aside from non-melanoma skin cancer, the risk for other cancers in RA patients on TNFi
was not increased [3,4].
Our study has several strengths. The ability to access and review the VA’s national patient
electronic medical record databases permitted the construction of a validated cohort of RA
patients with HNC who had or had not received a TNFi, and the evaluation of rare events such
as HNC using stringent inclusion and exclusion criteria. Our study period of ten years allowed
us to examine outcomes which may have long latency periods; in this case HNC recurrence or
death. We examined a comprehensive list of potential risk factors including age, smoking and
alcohol use, stage of cancer, treatment modalities, and a co-morbidity score as predictors of
HNC recurrence or death. Our VA cohort was inherently enriched for cases of HNC because it
consisted of predominantly male, Caucasian, older patients with RA who were smokers. These
factors that usually limit the external validity of findings in a VA cohort became strengths in
our study.
Our study has limitations as well. Given the observational nature of the study, there was a
potential for channeling bias. If a patient was at higher risk of HNC recurrence (older age, non-
Caucasian race, current smoker, recent diagnosis of HNC, advanced stage of HNC), a clinician
may have been less likely to consider using TNFi in such a patient, making TNFi appear safe.
The likelihood of such channeling bias is mitigated by the inclusion in our multivariate model
of known risk factors for recurrence, but some bias toward the null may still be present. There
is no generally accepted and validated standardized tool to measure RA severity in administra-
tive data, and RA severity may impact HNC recurrence or death; we could not examine this
variable as a risk factor given the retrospective nature of our study. We were unable to examine
the role of human papilloma virus infection, an important risk factor for HNC [15] given the
lack of information on this in our retrospective database.
Finally, our results may have been biased by unmeasured confounders such as disease dura-
tion, dose of and compliance with DMARDs, lack of quantification of tobacco and alcohol
exposure and inability to include them as time-varying co-variates, the relatively small sample
size, and missing data on tumor histology and staging in some cases; all unavoidable pitfalls
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because of the observational design of the study. Some veterans may have been treated outside
the VA system leading to information or classification bias. As this was an observational study,
and as some veterans use both VA and non-VA services, the duration of follow-up was vari-
able. Therefore it is likely that some events were missed because these occurred outside of VA
care. Furthermore, more recent prescriptions for TNFi or nbDMARDs would have had less fol-
low-up time to detect HNC recurrence or HNC-attributable death. These factors may have not
allowed an accurate estimation of the risk conferred by TNFi on recurrence or HNC-related
death in this cohort. However, the large size of the VA administrative databases allowed us to
assemble the largest cohort with RA and HNC to our knowledge to date. While the cohort was
relatively small, it is unlikely that such a cohort could be prospectively collected due to the
uncommon co-occurrence of these diseases. Ideally, results from this observational study
should be validated in larger, prospective, well-defined cohorts where some of these confound-
ers can be eliminated.
Conclusion
The results of this study suggest that TNFi use may be safe, and not associated with an
increased risk of recurrence or HNC-attributable death in patients with RA. Because of con-
cerns about the potential risk of malignancy recurrence with TNFi, many clinicians tend to
avoid using these drugs in RA patients with a history of malignancy. Based on our results, these
agents may be safe in patients with RA and HNC with close monitoring, especially as the time
interval between HNC treatment and non-recurrence increases. Given the near ubiquitous use
of TNFi in RA, there is a compelling need for further safety studies of TNFi in patients with
malignancy.
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